相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
20.0%
招募中
4
80.0%
暂无批准数据
- NS Pharma and NCNP presented 4.5-year clinical trial data for brogidirsen, an antisense oligonucleotide therapy for Duchenne muscular dystrophy patients with exon 44 skipping mutations. - Six participants maintained motor function scores on North Star Ambulatory Assessment and Performance of Upper Limb assessments throughout the extended treatment period. - The therapy demonstrated an acceptable safety profile with no serious adverse events related to long-term administration and no treatment discontinuations over 4.5 years. - Results support brogidirsen's potential to modify DMD disease progression, with a second global Phase II study currently underway to further evaluate efficacy.
- NS Pharma and NCNP presented 3.5-year clinical trial data for brogidirsen, an antisense oligonucleotide therapy for Duchenne muscular dystrophy patients amenable to exon 44 skipping. - The study demonstrated high exon 44 skipping efficiency and sustained dystrophin expression levels in muscle biopsies at both week 25/26 and week 99/100. - Ambulant participants maintained motor function over the long-term treatment period with no serious adverse events or treatment discontinuations reported. - The findings support brogidirsen's potential to modify DMD disease progression, with a global Phase II study currently underway.
- A 16-week clinical trial demonstrated that cognitive processing therapy combined with standard treatment significantly reduced PTSD symptoms compared to usual care alone in Japanese patients. - The study, conducted at a Tokyo psychiatric hospital, showed a marked decrease in CAPS-5 scores from 35.97 to 22.36 in the CPT group, while control group scores remained largely unchanged. - Beyond PTSD improvement, patients receiving cognitive processing therapy showed significant positive changes in depression, suicidal ideation, and overall disability measures, with no serious adverse events reported.
